|
Prescription Pharmaceutical Market Sales Overview – Analysis of prescription pharmaceutical sales across 12 major markets
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 302 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, havi.....
Introduction Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, having grown by 6.3% during 2008–09, and at a compound annual growth rate (CAGR) of 5.6% between 2005 and 2009. Features and benefits * Analyzes the size and growth (in terms of volume and value) of the 12 major prescription pharmaceutical markets* Examines the prescription pharmaceutical sales growth trends across the various different therapy areas* Assesses the leading prescription pharmaceutical brands across the each of the 12 major pharma markets* Profiles the leading multinational and domestic pharma companies operating in each of the 12 major pharma markets. Highlights The US prescription pharmaceutical market generated half (50.3%) of the sales of the 12 markets analyzed, with $279bn in 2009, with sales having grown by 5.0% (CAGR, 2005–09) and 5.5% (2008–09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.The five major European markets (UK, Germany, France, Italy and Spain) generated sales of $143bn in 2009. However, ongoing austerity measures targeted at reducing healthcare expenditure, through driving up generic penetration as well as price cuts (on branded and generic drugs) will dampen growth going forward.Growth in the emerging markets is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generics and branded pharmaceuticals. Your key questions answered * Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2015* Quantify the size and growth of the 12 major pharmaceutical markets, analyzing key therapy areas, brands and companies* Assess drivers and resistors of the prescription pharmaceutical market [Studien Infos ausblenden] |
|||||||||||
|
Executive Summary Introduction Strategic scoping and focus 12 Major markets – Key Findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies Related reports 4. 12 MAJOR MARKETS – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS 12 Major markets – Key Findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies 12 Major markets – Pharmaceutical market size The US pharmaceutical market while the largest will decline through 2015 Cost-containment policies throughout Europe translate in modest growth Brand loyal Japan aims to boost its generics industry Australia’s small pharmaceutical market is also undertaking cost-cutting measures The emerging markets showed the fastest growth rates Global forecast sales for the top 50 pharma companies 12 Major markets – Leading therapy areas The CNS and cardiovascular markets will experience sales declines out to 2015 due to increasing generic competition Metabolic, oncology and oncology markets driven by biologic sales growth Chinese medicines are the fastest growing drug group 12 Major markets – Leading pharmaceutical brands Lipitor is to experience a dramatic loss in sales due to its looming patent expiry Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline 12 Major markets – Leading pharmaceutical companies Pfizer Merck & Co. AstraZeneca GlaxoSmithKline Novartis Sanofi-Aventis Roche Johnson & Johnson Eli Lilly Takeda 3. US – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS US – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies US – Pharmaceutical market size US – Leading therapy areas Metabolic drugs exhibited the strongest sales growth during 2005–09 Central nervous system drugs hold the largest value share of the US market Cardiovascular drugs saw declining sales Leading therapy areas out to 2015 (for the top 50 pharma companies) US – Leading pharmaceutical brands Lipitor has suffered sales erosion die to availability of other generic statins Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are forecast to decline Plavix is the industry-leading antithrombotic and is supported by a wealth of post-launch data US – Leading pharmaceutical companies The top 10 pharmaceutical companies in the US Forecast sales for the top 10 pharmaceutical companies in 2015 The top 10 US-based pharmaceutical companies Pfizer Merck & Co. Johnson & Johnson 4. JAPAN – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Japan – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies Japan – Pharmaceutical market size Japan – Leading therapy areas Cardiovascular drugs hold the largest value share of the Japanese market Immunology and inflammation drugs have exhibited the fastest annual growth following approval of biologic drugs Oncology drugs will drive market growth out to 2015 The musculoskeletal market is contracting due to intensifying generic competition Leading therapy areas out to 2015 (for the top 50 pharma companies) Japan – Leading prescription pharmaceutical brands Blopress is the highest selling brand in Japan but its position may be in jeopardy from 2012 onwards Diovan has been growing strongly thanks to numerous indication approvals Lipitor maintains growth despite the availability of cheaper generic statins Japan – Leading pharmaceutical companies Roche and Eisai have experienced particularly strong growth in Japan Leading companies out to 2015 The leading domestic companies are exhibiting modest growth rates 5. FRANCE – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS France – Key findings Pharmaceutical market size Leading therapy areas Leading pharmaceutical brands Leading pharmaceutical companies France – Pharmaceutical market size France – Leading therapy areas Central nervous system was the largest therapy area in terms of sales Oncology drugs have shown the fastest growth rates Gastroenterology drugs have shown the sharpest decline in growth rates France – Leading pharmaceutical brands Plavix is the top-selling pharmaceutical brand, although its position will be jeopardized due to intensifying generic competition Lipitor will see a sharp decline in sales following the imminent patent expiry in 2011 Avastin’s impressive growth rates are set to continue in the future France – Leading pharmaceutical companies Sanofi-Aventis is the largest pharmaceutical company in France Mylan is the largest generics company in France The top 10 France-based pharmaceutical companies 6. GERMANY – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Germany – Key findings Pharmaceutical market size Leading therapy areas Leading pharmaceutical brands Leading pharmaceutical companies Germany – Pharmaceutical market size Germany – Leading therapy areas CNS drugs held the largest share of the German market value Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009 Oncology drugs exhibited the strongest sales over 2005–09 Gastroenterology market is contracting due to significant generic competition Germany – Leading pharmaceutical brands Humira’s leading position is likely to be maintained in the future Despite patent expiry in 2010, Enbrel’s growth is set to continue Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold-standard status Germany – Leading pharmaceutical companies Most of the top 10 companies have exhibited near-flat growth rates, with the notable exception of Novartis and Roche The leading domestic companies are largely generics or parallel importers 7. ITALY – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Italy – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies Italy – Pharmaceutical market size Italy – Leading therapy areas Cardiovascular drugs collectively hold the largest market share but have exhibited flat sales growth Musculoskeletal drugs exhibited the fastest sales and volume growth due to rapid uptake of a new first-in-class drug Gastroenterology market is contracting due to intensifying generic competition Italy – Leading pharmaceutical brands Lipitor is the top selling brand and is set to maintain its position in Italy due to strong brand loyalty Herceptin’s strong sales growth is attributed to superior efficacy and unbeatable gold standard status Eprex has exhibited solid growth although its future position remains uncertain due to fierce competition Italy – Leading pharmaceutical companies The leading international companies hold the lion’s share of the Italian pharmaceutical market The leading domestic companies are exhibiting faster growth rates 8. SPAIN – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Spain – key findings Pharmaceutical market size Leading therapy areas Leading pharmaceutical brands Leading pharmaceutical companies Spain – pharmaceutical market size Spain – leading therapy areas CNS was the largest therapy area in terms of sales The CNS market was the largest therapy area in Spain, generating $4.2bn in sales during 2009, with a sales CAGR of 6.6% from 2005 to 2009, and an annual growth rate of 4.2% (2008–09) (MIDAS sales data, IMS Health, March 2010). This is largely attributed to brands such as Risperdal (risperidone, Johnson & Johnson), Zyprexa (olanzapine, Eli Lilly), and Lyrica (pregabalin, Pfizer), with all three drugs featured among the 20 top selling pharmaceutical brands in Spain. The musculoskeletal market is being driven by rapid uptake of osteoporosis treatments The immunology and inflammation market is being driven by several innovative drugs The gastroenterology market is contracting due to intensifying generic competition Spain – leading pharmaceutical brands Lipitor is the top selling brand but its looming patent expiry may jeopardize its leading position Plavix is starting to face considerable generic competition in Spain Humira’s strong position is likely to be maintained in the future Spain – leading pharmaceutical companies Pfizer was the largest pharmaceutical company in Spain Roche's sales have been driven by the rapid uptake of monoclonal antibodies The top 10 Spain-based pharmaceutical companies 9. UK – PRESCRIPTION PHARMACEUTICAL SALES ANALYSISUK – KEY FINDINGS [Missing title] Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies UK – Pharmaceutical market size UK – Leading therapy areas Central nervous system drugs hold the largest share of the UK market value Oncology drugs exhibited the strongest sales during 2005–09 Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009 Gastroenterology and cardiovascular drugs saw declining sales UK – Leading pharmaceutical brands Leading brand Seretide may face competition from faster-growing Symbicort Lipitor has begun to suffer from sales erosion from other generic statins Enbrel’s solid growth is attributed to its superior efficacy and having secured approval for multiple indications UK – Leading pharmaceutical companies The top 10 companies struggle to maintain growth momentum The leading domestic companies experience impressive growth 10. AUSTRALIA – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Australia – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies Australia – Pharmaceutical market size Australia – Leading therapy areas Cardiovascular drugs hold the largest share of the Australian market value Central nervous system products hold the second-largest share of the Australian market value Musculoskeletal drugs exhibited the strongest growth in sales in 2005–09 and 2008–09 The hematology class experienced the most rapid decline in growth Australia – Leading pharmaceutical brands Lipitor achieved by far the highest sales in Australia in 2009, but generics are expected in 2012 Crestor experiences a huge uptake in sales but may face price cuts and uncertain patent protection Nexium’s sales are going strong despite its price being linked to generic omeprazole Australia – Leading pharmaceutical companies Leading international companies active in Australia account for 63% of the pharmaceutical market Leading Australian companies only make up 7% of the Australian pharmaceutical market 11. BRAZIL – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Brazil – Key findings Pharmaceutical market size Leading therapy areas Leading pharmaceutical brands Leading pharmaceutical companies Brazil – Pharmaceutical market size Brazil – Leading therapy areas Central nervous system was the largest therapy area in terms of sales Musculoskeletal drugs have shown the fastest growth rates Urology and metabolic have shown the slowest growth rates Brazil – Leading pharmaceutical brands Top-selling drug Dorflex sees its franchise extended with follow-up product Cialis to maintain momentum thanks to lifecycle management strategy Lipitor is expected to continue reaching high sales even after patent expiration Brazil – Leading pharmaceutical companies Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley Novartis’s Brazilian retail sales growth driven by its Diovan franchise The leading domestic companies are exhibiting double-digit growth rates 12. RUSSIA – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS Russia – Key findings Pharmaceutical market size Leading therapy areas Leading pharmaceutical brands Leading pharmaceutical companies Russia – Pharmaceutical market size Russia – Leading therapy areas Central nervous system drugs hold the largest share of the Russian market value Infectious disease drugs exhibited the strongest annual sales growth (2008–09) Hematology drugs showed the fastest growth in terms of sales CAGR (2005–09) Russia – Leading pharmaceutical brands Velcade was the top selling brand in Russia Octavi exhibited the strongest sales CAGR of the top 20 brands, but faces competition from its follow-on product Glivec’s gold-standard position drives uptake Russia – Leading pharmaceutical companies The leading international companies offer both innovative therapies and generic products Domestic companies offer largely generic and consumer healthcare products 13. INDIA – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS India – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies India – Pharmaceutical market size India – Leading therapy areas Infectious diseases drugs hold the largest value share of the Indian market Musculoskeletal drugs have exhibited the fastest annual growth Uptake of oncology drugs is growing rapidly albeit from a very low base India – Leading prescription pharmaceutical brands Phensedyl cough and Corex dominated the respiratory market in India Human Mixtard 30/70 has been growing strongly as diabetes rates increase India – Leading pharmaceutical companies Leading international companies in India The leading domestic companies are exhibiting modest growth rates 14. CHINA – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS China – Key findings Pharmaceutical market size Leading therapy areas Leading prescription pharmaceutical brands Leading pharmaceutical companies China – Pharmaceutical market size China – Leading therapy areas Infectious diseases drugs hold the largest share of the Chinese market value Traditional Chinese medicines (TCMs) exhibited the strongest sales during 2005–09 China – Leading pharmaceutical brands Shu Xue Ning achieved by far the highest sales in China in 2009 Ke Lin Ao Plavix – FDA ‘black box’ warning may influence its sales in China China – Leading pharmaceutical companies The leading international companies held almost 18% of Chinese value market in 2009 The leading domestic companies experienced impressive growth Shandong Qilu Pharma Jiangsu Yangzijiang Pharma 15. BIBLIOGRAPHY [Missing title] Publications and online articles Datamonitor reports and products US – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products Japan – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products France – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products Germany – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products Italy – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products Spain – Prescription pharmaceutical sales Publications and online articles Datamonitor reports and products UK – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products Australia – Prescription pharmaceutical sales analysis Publications and online articles Brazil – Prescription pharmaceutical sales analysis Publications and online articles Russia – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products India – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products China – Prescription pharmaceutical sales analysis Publications and online articles Datamonitor reports and products APPENDIX Datamonitor prescription pharmaceutical definition and therapy area classification [Inhaltsverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
